NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
NeOnc Technologies appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its board effective October 9, 2026, succeeding Dr. Steven L. Giannotta, who remains on the Scientific Advisory Board. The company disclosed that Abu Dhabi's health regulator granted IND authorization supporting NEO212 development in the UAE, and an End-of-Phase 1 Type B FDA meeting on NEO212 is set for November 17, 2026.
Key figures
- Drug Name
- NEO212
- Phase Of Trial
- Phase 1 completed (dose escalation), advancing toward Phase 2
- Neo100 patients
- 24
- Neo100 phase2a pfs 6mo
- 48.9%
- Neo100 phase2a median os
- 26.09 months
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.